We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current CTNM market cap is 210.02M. The company's latest EPS is USD 1.7276 and P/E is 9.24.
Quarter End | |
---|---|
USD (US$) | |
Total Revenue | |
Operating Income | |
Net Income |
Year End 31 December 2023 | 2023 |
---|---|
USD (US$) | |
Total Revenue | 50M |
Operating Income | 16.08M |
Net Income | 22.72M |
Quarter End | |
---|---|
USD (US$) | |
Total Assets | |
Total Liabilities | |
Total Equity |
Year End 31 December 2023 | 2023 |
---|---|
USD (US$) | |
Total Assets | 130.39M |
Total Liabilities | 5.7M |
Total Equity | -67.94M |
Market Cap | 210.02M |
Price to Earnings Ratio | 9.24 |
Price to Sales Ratio | 4.2 |
Price to Cash Ratio | 13.53 |
Price to Book Ratio | 1.68 |
Dividend Yield | - |
Shares Outstanding | 13.15M |
Average Volume (1 week) | 20.82k |
Average Volume (1 Month) | 49.8k |
52 Week Change | 10.14% |
52 Week High | 16.4622 |
52 Week Low | 13.27 |
Spread (Intraday) | 0.49 (3.06%) |
Company Name | Contineum Therapeutics Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.contineum-tx.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions